# About RegenLife Peptides — An Independent Tissue-Repair Research Desk

> About RegenLife Peptides: an independent literature briefing on four Recovery & Tissue Repair research peptides. How it is compiled, what it covers, and what it is not — not a seller, not a clinic, not medical advice.

An independent, citation-anchored briefing on four tissue-repair research peptides. Not a vendor. Not a clinic. Not medical advice.

## What RegenLife Peptides is

RegenLife Peptides is an independent editorial briefing covering the published and preclinical research on four compounds studied for tissue repair and regeneration: BPC-157, GHK-Cu, the GLOW blend, and the Wolverine blend, with BPC-157 as the lead. The desk exists to make a frequently overstated literature legible — to state, in a clinician's-briefing style, what each compound was actually studied for, in which species, and how far that evidence honestly reaches.

The organizing idea is regenerative and tissue-repair research, mapped for newcomers: two single compounds with genuinely different mechanisms (BPC-157's angiogenic profile, GHK-Cu's matrix-remodeling profile) and two research-community combinations (GLOW, Wolverine) built from those same compounds plus TB-500. Reading all four together clarifies which claims rest on controlled human trials, which rest on animal data, and which rest on nothing but a combination theory. Each compound has its own page; a comparison page lines up all four; and a single shared references list aggregates every source used across the site.

## How it is compiled

Three principles govern this desk. First, every research claim is anchored to a numbered citation — peer-reviewed journal articles, systematic reviews, and pharmacokinetic studies, with DOIs and PubMed links, collected on the references page. Second, evidence is described at its actual strength: a two-person intravenous safety pilot is labeled as exactly that, not generalized into a safety guarantee; a rodent tendon-repair study is labeled as a rodent study. Third, the four pages are cross-referenced, because the same peptides — BPC-157 and TB-500 in particular — recur across multiple pages, and the desk links between them rather than repeating claims in isolation.

## What it is not

RegenLife Peptides is not a pharmacy, a clinic, a telehealth platform, or a vendor of any kind. It does not sell, supply, source, or broker any peptide, and has no affiliate or referral relationship with any research-chemical supplier. It does not employ clinicians, diagnose conditions, or prescribe anything, and it does not recommend a dose, schedule, or route of administration for any person.

None of the four compounds covered here is an FDA-approved medicine. Readers seeking clinical guidance should consult a licensed healthcare provider in their own jurisdiction. Editorial correspondence on citation corrections or newly published research can be directed to the [contact page](/contact); this desk monitors that correspondence carefully but cannot respond to requests for medical advice.

---

A clinician's-briefing digest on tissue-repair research peptides — read it for citations, not for a treatment plan.